HTG Molecular Diagnostics (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene expression assays on HTG's fully automated, extraction-free Edge platform.
The HTG Edge system is the only extraction-free, automated gene expression platform that delivers affordable, multiplexed results on lysed samples in less than a day. The Edge System’s multiplexing capability utilizing only one five-micron thick FFPE section provides a unique solution for the clinical laboratory professional.
OvaGene Oncology is entirely dedicated to helping women with gynecologic cancers by providing their treating oncologists with molecular tests developed using the latest advancements in gene-based diagnostics.
OvaGene CEO Frank Kiesner said: "We recognized right away that HTG’s technology would help us improve our workflow and reduce turnaround time to our customers and ultimately patients while providing superior quality data. In addition, the system will allow us to expand our specimen type to ascites and smaller samples such as biopsies."